company background image
SANA logo

Sana Biotechnology NasdaqGS:SANA Stock Report

Last Price

US$1.61

Market Cap

US$359.5m

7D

-1.2%

1Y

-60.5%

Updated

30 Dec, 2024

Data

Company Financials +

Sana Biotechnology, Inc.

NasdaqGS:SANA Stock Report

Market Cap: US$359.5m

SANA Stock Overview

A biotechnology company, focuses on utilizing engineered cells as medicines. More details

SANA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Volatile share price over the past 3 months compared to the US market

Shareholders have been diluted in the past year

Has less than 1 year of cash runway

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Sana Biotechnology, Inc. Competitors

Orchard Therapeutics

NasdaqCM:ORTX

US$380.1m

Taysha Gene Therapies

NasdaqGS:TSHA

US$358.7m

Prime Medicine

NasdaqGM:PRME

US$370.0m

Korro Bio

NasdaqCM:KRRO

US$374.7m

Price History & Performance

Summary of share price highs, lows and changes for Sana Biotechnology
Historical stock prices
Current Share PriceUS$1.61
52 Week HighUS$12.00
52 Week LowUS$1.52
Beta1.32
1 Month Change-42.09%
3 Month Change-62.03%
1 Year Change-60.54%
3 Year Change-89.67%
5 Year Changen/a
Change since IPO-95.41%

Recent News & Updates

Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus

Dec 04

Sana Biotechnology: The Story Becomes Murkier

Nov 19

We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully

Nov 01
We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully

Recent updates

Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus

Dec 04

Sana Biotechnology: The Story Becomes Murkier

Nov 19

We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully

Nov 01
We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

Jul 14

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Jul 12
We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Sana Biotechnology: Now In Overbought Territory

Mar 17

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Jan 11

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Dec 30
Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 14
Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

May 26
Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Dec 19
We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 03
Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sana Biotechnology A Buy For Potential Cancer Therapies

Jun 27

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

May 16
Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Sana Biotechnology: Exciting Preclinical Science

Feb 12

Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?

Oct 13
Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?

Sana Biotechnology: Hypoimmune Cell Therapies

Jul 01

Sana Biotechnology reports Q1 results

May 05

Shareholder Returns

SANAUS BiotechsUS Market
7D-1.2%-1.7%-1.1%
1Y-60.5%-5.0%22.4%

Return vs Industry: SANA underperformed the US Biotechs industry which returned -3.4% over the past year.

Return vs Market: SANA underperformed the US Market which returned 23.7% over the past year.

Price Volatility

Is SANA's price volatile compared to industry and market?
SANA volatility
SANA Average Weekly Movement12.3%
Biotechs Industry Average Movement10.8%
Market Average Movement6.3%
10% most volatile stocks in US Market17.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: SANA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: SANA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2018328Steve Harrwww.sana.com

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company’s product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin’s lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others.

Sana Biotechnology, Inc. Fundamentals Summary

How do Sana Biotechnology's earnings and revenue compare to its market cap?
SANA fundamental statistics
Market capUS$359.46m
Earnings (TTM)-US$305.81m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.2x

P/E Ratio

Is SANA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SANA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$305.81m
Earnings-US$305.81m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.37
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did SANA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 03:28
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sana Biotechnology, Inc. is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBofA Global Research
Alec StranahanBofA Global Research
Samantha Lynn SemenkowCitigroup Inc